Drug Combo Proves Powerful Against Lung Cancer Lindenhurst NY

A two-drug combination treatment in Lindenhurst proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

HERBERT AUSUBEL, MD
(516) 561-8188
509 W Merrick Road
Valley Stream, NY
ABDUL MUNDIA, MD
(516) 763-1962
2000 N Village Avenue
Rockville Centre, NY
Kenneth Ng, MD
516-256-3651
1000 N Village Ave
Rockville Centre, NY
Paul Arthur Feffer, MD
516-365-3411
7 Wimbledon Dr
Roslyn, NY
Anna Kurzyna-Solinas, MD
516-466-6611
600 Northern Blvd
Great Neck, NY
Richard M Lee
(516) 536-1455
242 Merrick Rd
Rockville Centre, NY
SHABEER DAR, MD
(631) 376-1101
400 Montauk Highway
West Islip, NY
EDWARD CHAN, MD
(631) 444-7720
University Hospital
Stony Brook, NY
Loren Scott Michel, MD
Apt F-02 200 Carmen Ave
East Meadow, NY
Hasan Rizv, MD
631-666-0262
180 E Main St
Bay Shore, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Breast Cancer Survival Lindenhurst NY
Breast cancer is a physically and emotionally traumatizing disease. A study underrtaken at the Harvard School of Public Health examined four observational studies to determine whether physical activity could improve quality of life after a breast cancer diagnosis and on increased breast cancer survival.
- Risks for Childhood Cancer Survivors Lindenhurst NY
- Side Effect Of Chemotherapy Drugs Lindenhurst NY
- Hormone Therapy for Lung Cancer Lindenhurst NY
- Delayed Prostate Cancer Therapy Lindenhurst NY
- Fungal Infection Treatments Lindenhurst NY
- Genetic Clues for Skin Cancer Therapies Lindenhurst NY
- Hormone Therapy for Breast Cancer Lindenhurst NY
- Exercise for Prostate Cancer Lindenhurst NY